Loading stock data…
$4.19-0.05 (-1.18%)
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders.
Opus Genetics, Inc. in the Healthcare sector is trading at $4.19 with a market capitalization of $301M. Wall Street consensus targets $13.41 (17 analysts), implying a +220.1% move over the next 12 months. The stock is currently 41% below its 52-week high of $7.07, remaining 2.7% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $755,000↓ | $2.16M↓ | $3.87M↑ | $3.08M↑ | $2.88M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$16.48M↓ | -$14.36M↓ | -$11.45M↓ | -$8.31M↑ | -$8.91M |
| Net Income | -$8.10M↑ | -$65.53M↓ | -$16.52M↑ | -$17.45M↓ | -$7.42M |
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It d...